נולוג'יקס 250 מ"ג

Ülke: İsrail

Dil: İbranice

Kaynak: Ministry of Health

Aktif bileşen:

BELATACEPT 25 MG/ML

Mevcut itibaren:

BRISTOL-MYERS SQUIBB (ISRAEL) LIMITED

ATC kodu:

L04AA28

Farmasötik formu:

POWDER FOR CONCENTRATE FOR INFUSION

Uygulama yolu:

I.V

Tarafından üretildi:

BRISTOL-MYERS SQUIBB S.R.L, ITALY

Terapötik grubu:

BELATACEPT

Terapötik endikasyonlar:

Nulojix, in combination with corticosteroids and mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen

Yetkilendirme tarihi:

2012-08-01